SERPIN PHARMA, LLC
Biotech · Private
SP16, a small-molecule LRP1 agonist therapeutic to prevent chemotherapy-induced peripheral neuropathy
- Grants
- $1.9M
- 3 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 7 granted · 17 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Pre-clinical validation of Phase II peptide LRP-1 agonist to treat and prevent chemotherapy induced peripheral neuropathy. | $398,816 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel LRP1 Agonist, SP16, as a Therapeutic Treatment in Preventing Chemotherapy-Induced Peripheral Neuropathy | $838,708 | |
| Federal grant | Department of Health and Human Services · Phase II · A Novel LRP1 Agonist, SP16, as a Therapeutic Treatment in Preventing Chemotherapy-Induced Peripheral Neuropathy | $625,359 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2387 | Rakuten Medical, Inc. | — | $887M |
| 2388 | Avalo Therapeutics | — | $182M |
| 2389 | MOCKV SOLUTIONS INC. | — | — |
| 2390 | SERPIN PHARMA, LLC | — | — |
| 2391 | ZENO MANAGEMENT, INC | — | — |
| 2392 | CH3 BIOSYSTEMS, LLC | — | — |
| 2393 | Autifony Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Serpin Peptide Derivatives And Methods Of Using The Sameapplication
- Serpin Peptides And Methods Of Using The Sameapplication
- Methods For Treatment Of Diseasesapplication
- Serpin Peptides And Methods Of Using The Sameapplication
- Serpin Peptides And Methods Of Using The Samegranted
- Peptides And Methods Of Using The Sameapplication
- Serpin Peptides And Methods Of Using The Sameapplication
- Peptides And Methods Of Using The Samegranted
- Methods For Treatment Of Diseasesapplication
- Methods For Treatment Of Diseasesgranted
- Peptides And Methods Of Using Samegranted
- Peptides And Methods Of Using Samegranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.